Last updated on March 2020

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)


Brief description of study

This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).

The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.

Clinical Study Identifier: NCT03651128

Find a site near you

Start Over

Thomas Jefferson University

Philadelphia, PA United States
  Connect »

Moffit Cancer Center

Tampa, FL United States
  Connect »

Mount Sinai Medical Center

New York, NY United States
  Connect »

Emory University Hospital

Atlanta, GA United States
  Connect »

MD Anderson Cancer center

Houston, TX United States
  Connect »

Swedish Cancer Institute

Seattle, WA United States
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

Mayo Clinic Arizona

Scottsdale, AZ United States
  Connect »

Mayo Clinic - Jacksonville

Jacksonville, FL United States
  Connect »

Mayo Clinic - Rochester

Rochester, MN United States
  Connect »

Fox Chase Cancer Center

Philadelphia, PA United States
  Connect »

Tokai University Hospital

Isehara, Kanagawa, Japan
  Connect »

Mass General

Boston, MA United States
  Connect »

CHRU Lille

Lille Cedex, France
  Connect »

Oslo universitetssykehus, Rikshospitalet

Oslo Universitetssykehus, Rikshospitalet, Norway
  Connect »

IUCT Oncopole

Toulouse CEDEX 9, France
  Connect »

Erasmus Medical Center

Rotterdam, Netherlands
  Connect »